Physician

Miguel Albino, MD

According to 2025 Medicare claims, Miguel Albino, MD (NPI: 1205060746) practices medical oncology in the Austin-Round Rock-San Marcos, TX market, with the plurality of this provider's patient population coming from Travis, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1972770303; TIN: 752131429) and primary practice location at 78758-5453.

Albino's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 430 traditional Medicare patients, billed 181,220 HCPCS/CPT codes, and received $3,115,793 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 761 prescription claims across 137 beneficiaries totaling $938,091 in drug costs, led by Revlimid (Lenalidomide). DME data shows 28 claims. Open Payments data shows 152 records totaling $41,423. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $228,893 to $3,115,793. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $128,443 and ending at $938,091. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	140	22,570	$228,893
2017	330	46,929	$685,485
2018	437	51,303	$952,299
2019	484	44,096	$862,346
2020	412	66,438	$877,198
2021	415	122,786	$1,405,665
2022	445	150,073	$1,821,303
2023	388	142,677	$2,138,843
2024	430	181,220	$3,115,793

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	22	93	$128,443
2017	133	556	$546,842
2018	187	1,041	$1,267,392
2019	188	1,041	$1,473,851
2020	134	566	$794,938
2021	98	482	$267,289
2022	123	773	$761,956
2023	120	743	$334,734
2024	137	761	$938,091

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	11	$5,033
2023	N/R	12	$8,096
2024	N/R	28	$890

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	142	520	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	133	331	$94
80053	Blood test, comprehensive group of blood chemicals	124	360	$10
36415	Insertion of needle into vein for collection of blood sample	127	419	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	130	418	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	30	700	$491,999
Eliquis	Apixaban	49	2,131	$37,251
Xarelto	Rivaroxaban	29	1,320	$23,829
Creon	Lipase/Protease/Amylase	13	347	$19,100
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	32	409	$771

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	14	$627
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	152	$41,423	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Miguel Albino, MD?

Tedicare shows public-source Medicare data for Miguel Albino, MD (NPI 1205060746), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Miguel Albino, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Miguel Albino, MD?

Miguel Albino, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1972770303) in the available physician profile data.

Does Miguel Albino, MD have Open Payments data?

Miguel Albino, MD has 152 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.